Publication in "Nature–Scientific Reports"
Epalinges, Switzerland, March 24, 2022 - Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome based vaccines and immunotherapies against human life disabling and infectious diseases, announced today a publication in Nature Scientific Reports in collaboration with the AMC – Amsterdam University Medical Center, with title: “A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike”.
Publication in "Frontiers in Immunology"
Epalinges, Switzerland, February 22, 2022 - Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome based vaccines and immunotherapies against human life disabling and infectious diseases, announced today a publication in Frontiers in Immunology with title: “Cooperation between Systemic and Mucosal Antibodies Induced by Virosomal Vaccines Targeting HIV-1 Env: Protection of Indian Rhesus Macaques against Mucosal SHIV challenges”
Publication in "Clinical & Experimental Allergy"
Epalinges, January 5, 2021: Following two successful studies with its virosome platform, Mymetics announces the acceptance of its joint publication in the scientific journal Clinical & Experimental Allergy with Stallergenes Greer SA and Anergis SA, with the title: Bet v 1 contiguous overlapping peptides anchored to virosomes with TLR4 agonist enhance immunotherapy efficacy in mice.
Publication in "nature.com/npjvaccines"
Epalinges, January 31, 2020: Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against Plasmodium falciparum parasites in preclinical in vitro and in vivo models
Mymetics announces publication in npj - Vaccines “New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes”
Epalinges, Switzerland, 18 May 2020 – Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome based vaccines and immunotherapies against human life disabling and infectious diseases, announced today a publication in Nature Partner Journals “Vaccines” describing the results from a new GMP manufacturing process to obtain thermostable HIV-1 gp41 virosome vaccines under solid forms and various mucosal vaccination routes
WORLD MALARIA DAY
Epalinges, Switzerland, April 25, 2019 – Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling human diseases has learned that there is inaccurate information in the public domain. Mymetics is dedicated to develop vaccines for life threatening and disabling diseases based on our virosome virus like particle platform.
Material Incorrect Information in Public Domain
Epalinges, Switzerland, July 26, 2018 - Material Incorrect Information in Public Domain
Development of a Virosomal RSV Vaccine Containing 3D-PHAD® Adjuvant: Formulation, Composition, and Long-Term Stability
June 26th, 2018 - Characterization of virosomes, in late stage preclinical development as vaccines for Respiratory Syncytial Virus (RSV), with a membrane-incorporated synthetic monophosphoryl lipid A, 3D-PHAD® adjuvant.
Particle based platforms for malaria vaccines
December 22nd, 2015 - Particle based malaria vaccines
A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats
Respiratory syncytial virus (RSV) has been recognized as an important vaccine target for over 60 years; however, there is no vaccine on the market today.
Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats
Respiratory syncytial virus infection remains a serious health problem, not only in infants but also in immunocompromised adults and the elderly. An effective and safe vaccine is not available due to several obstacles: non-replicating RSV vaccines may prime for excess Th2-type responses and enhanced respiratory disease (ERD) upon natural RSV infection of vaccine recipients.
Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes
The human immunodeficiency virus type 1 (HIV-1) is mainly transmitted through sexual contact. To infect its host, HIV-1 employs its viral membrane surface trimeric envelope glycoprotein, composed of the receptor binding domain gp120 and the membrane anchored fusion protein subunit gp41.
Immunogenicity and Protective Capacity of a Virosomal Respiratory Syncytial Virus Vaccine Adjuvanted with Monophosphoryl Lipid A in Mice
Respiratory Syncytial Virus (RSV) is a major cause of viral brochiolitis in infants and young children and is also a significant problem in elderly and immuno-compromised adults.
Virosome-Formulated Plasmodium falciparum AMA-1 & CSP Derived Peptides as Malaria Vaccine: Randomized Phase 1b Trial in Semi-Immune Adults & Children
The development of an effective malaria vaccine is regarded as one cornerstone in the fight against this deadly disease and to achieve its eventual elimination.
Immunization with HIV-1 gp41 Subunit Virosomes Induces Mucosal Antibodies Protecting Nonhuman Primates against Vaginal SHIV Challenges
Human immunodeficiency virus (HIV)-1 is mainly transmitted mucosally during sexual intercourse. We therefore evaluated the protective efficacy of a vaccine active at mucosal sites.